• VPRB’s CEO brings to the team 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing
• The company’s COO played a pivotal role in launching VPR Brands’ cannabis-based product division
• VPR Brands has seen impressive quarterly results and is positioned as an up-and-coming player in the cannabis industry

VPR Brands LP (OTC: VPRB), an innovative technology holding company, has partnered with top international brands in an effort to rise to the top of the booming cannabis industry. The company’s assets include issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and electronic cigarette products and components.

The company currently boasts a strong portfolio of unique brands and is led by a team of seasoned industry professionals. CEO Kevin Frija has decades of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, he became the president and chief executive officer of Vapor Corp., one of the first publicly traded electronic-cigarette companies. In 2016, Frija purchased the brands and wholesale business assets of Vapor Corp., which is now owned by VPR Brands. He currently leads VPR Brands as it creates inroads into the cannabis industry, a move that is bringing the company increasing sales and profit margins.

Chief Operating Officer Dan Hoff brings valuable experience working in the vaporizer and e-cigarette industry to VPR Brands. He has held various leadership positions at Vapor Corp., including overseeing financial management, accounting functions, supply chain management, product design and development, and key vendor relations. His role in the construction and expansion of VPR Brands’ cannabis-based product division has been instrumental in helping the company pivot toward cannabis products.

VPR Brands’ industry potential has been flying under the radar, but, owing to its experienced leadership and strong brand portfolio, the company has posted impressive quarterly results. First-quarter 2019 results revealed increased revenues, indicating a nearly 31 percent year-over-year increase to $1.3 million. Additionally, the company lowered its net loss from approximately $149,000 in 2018 to approximately $138,000 in 2019 (http://ibn.fm/rSa7Z). The company continues to maintain strong gross operating margins above 40 percent.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• Technology investment enterprise SinglePoint recently reported that its Direct Solar subsidiary recorded $1.7 million in solar installation contracts during a 30-day period, causing the company to ratchet up its revenue forecasts for the year
• The company expects to see about $803,769 in gross revenue and $361,541 in net profit from the contracts
• SinglePoint has also been focusing on the development of the hemp market, as hemp legalization in the United States has created a new pathway for agricultural profits
• SinglePoint’s ‘Strategics’ program, in cooperation with a national distribution partner that has access to several large retail chains, is providing a pathway to store shelves for startups

Innovative technology investment enterprise SinglePoint Inc. (OTCQB: SING) is celebrating the success of its bet on solar power broker Direct Solar, a company that uses the Lending Tree model of connecting loan seekers to a variety of loan providers nationwide to allow them to effectively shop for a service that most closely fits their needs.

SinglePoint acquired Direct Solar in April with expectations that sales would exceed $8.2 million during the four quarters following closure of the agreement (http://ibn.fm/dp85r), but Direct Solar “surpassed everyone’s expectations” by signing contracts to deploy $1.7 million in solar installations over a 30-day period ending in June, putting the company on course to profitability from a cashflow standpoint more quickly than anticipated.

“This acquisition puts SinglePoint on a huge trajectory path. This is not only a home run, but a grand slam in our eyes,” CEO Greg Lambrecht stated in a news release issued by the company on June 18 (http://ibn.fm/6LCu3). “These revenues and profits provide SinglePoint the ability to be in a profitable cash flow position and the opportunity to aggressively expand sales. For every dollar we are putting into marketing we are seeing a return of five.”

The company expects to see about $803,769 in gross revenue and $361,541 in net profit from the sales. Direct Solar is also preparing to add operations in Missouri and Florida to the six states where it has been brokering residential installations, a move that it expects to generate additional explosive revenue.

In addition to SinglePoint’s support for the clean energy interests of solar power customers, the company has been dedicating a significant measure of its focus to the hemp market, seeking a place in the burgeoning cannabidiol (CBD) supply chain that New York-based investment bank Cowen & Co. foresees as pulling in $15 billion by 2025 and researchers at BDS Analytics and Arcview Market Research predict could reach $20 billion by 2024 (http://ibn.fm/DoKsw).

According to SinglePoint, Direct Solar is now negotiating a line of credit for cannabis businesses and other small businesses that would allow Direct Solar to not only generate the sale but the ability to provide the financing for these business owners as well. The cannabis industry has long suffered from difficulty in completing transactions because of the banking industry’s general unwillingness to support businesses that can’t qualify for the federal government’s deposit insurance backing in light of the government’s prohibition of cannabis-related sales.

The federal government’s passage of the 2018 Farm Bill and its attendant approval of hemp cultivation as an agricultural product provided encouragement to farmers and ancillary businesses to support hemp as an alternative agricultural product – one that’s in steady demand from consumers as of late (http://ibn.fm/bx3kd).

SinglePoint’s ‘Strategics’ program is an effort to provide a pathway to market through a national distribution partner for qualifying companies with annual revenue above $2 million. The partner has access to chain outlets such as CVS, Walgreens, Rite-Aid, Dollar Tree and Kroger grocery stores.

“Until now, startup, established and fast-growing CBD product companies have faced tremendous challenges in growing their business beyond e-commerce and regional distribution due to the enormous capital and logistics involved,” SinglePoint President Wil Ralston added (http://ibn.fm/2fLLr).

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• The Green Organic Dutchman is building a name for itself as it works on production build-up from 2,000 kilograms of cannabis to 200,000 kilograms
• The company has facilities in Canada and is making inroads in Europe and Mexico through pharmaceutical networks
• In the United States, TGOD is finding access to the $20 billion functional beverage industry segment

The advent of indoor cultivation that’s suitable for the cannabis industry has changed the commercial production capacity of marijuana and medical-grade cannabis suppliers. While the cannabis plant seeks the sun during the height of summer then flowers as the season ebbs, indoor cultivation technologies are allowing producers to grow the plant with a sharply increasing lifestyle appeal during virtually any season of the year.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is making a name for itself as it pursues an upward scaling strategy of building enclosed facilities for cannabis growth, anticipating that its purpose-built enterprise will progress from about 2,000 kilograms (4,400 pounds) of cannabis at its Ontario site this summer to 100 times that amount across all its sites when it reaches full capacity (http://ibn.fm/gLexA).

The Canada-based company, commonly known by ticker ‘TGOD’, is expanding its footprint to international markets, principally through wholly owned subsidiary HemPoland, which inked an agreement last month with Germany’s Mediakos UG haftungsbeschraenkt for the distribution of TGOD’s premium hemp-derived cannabidiol (CBD) brand, CannabiGold, to that country’s pharmacy market (http://ibn.fm/KHAmq). The company’s hemp oil extraction facility in Poland offers the potential of expansion throughout Europe and in other global markets with official PL-EKO-01 European Union certificates.

Through a joint venture with Mexico’s LLACA Grupo Empresarial, the company is reaching 4,500 pharmacies and 3,100 supermarkets throughout that country with its medicinal cannabis and hemp-derived wellness products.

The Green Organic Dutchman has also been operating two retail stores in Jamaica, where cannabis tourism goes hand-in-hand with sun-seeking travelers drawn to the island’s promise of idyllic rest and relaxation (http://ibn.fm/4Ba9j). Through a partnership with Symrise Inc., TGOD is also finding access to the $20 billion U.S. functional beverage category, including wellness, energy and sport recovery products (http://ibn.fm/HS5if).

The company aims to become the global leader in providing premium organic cannabis solutions for the betterment of people’s lives around the globe, building on applicable licenses in Canada and targeted partnerships in other countries.

“Through our certified organic product and process we know we are providing patients the best possible experience,” Chief Science Officer Dr. Rav Kumar stated in an interview with Proactive Investors (http://ibn.fm/AVbL4).

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Geyser Brands focuses on creating first-rate, cannabis-led health care products and brands
• The company leverages a proprietary, all-natural NanoFusion nano-emulsion delivery system
• Geyser is pursuing an acquisition of Solace Management Group Inc.

Geyser Brands Inc. (TSX.V: GYSR) is a foremost consumer health care company based in Vancouver, British Columbia. The company has an integrated production chain and formulation lab that develops unique products using hemp cannabidiol (CBD) for healthy lifestyle brands. Fundamentally, Geyser Brands builds and markets some of the leading cannabis products and brands in the world. Its proprietary nanotechnology formulations create products with superior bioavailability and efficacy. The company’s vision is to secure top positions in every market it enters (http://ibn.fm/CZOX6).

Geyser’s NanoFusion advanced delivery system rapidly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency. NanoFusion provides premier bioavailability and solves problems with insolubility. It also provides a longer shelf life, stability of molecules and enhanced permeation that allows for deeper skin penetration. Moreover, NanoFusion​ improves the transport of active ingredients for site-specific targeting and delivers active ingredients across cell membranes for release within the cell. Its proprietary process creates the only all-natural nano-emulsion on the market.

Geyser Brands’ acquisition target is Solace Management Group Inc. Solace owns a varied set of brands and is a leader in cannabis product formulations and development. Its brands span the adult-recreational and medical cannabis markets, as well as pet-health and wellness and hemp markets. Solace’s brands include Apawthecary Pets, WildTails pet products, Apothecary Naturals and Apothecary Ink.

Solace’s cosmetics line is Apothecary Naturals, whose products include pain creams, lip balms and skin health products for men and women. Its pet line, Apawthecary Pets, supplies leading retail stores and vets in Canada with products for pain and anxiety. Its baked pet treats use a proprietary process for baking in the hemp without degrading the molecule, delivering dosage control and better quality.

Geyser Brands’ global market focus is hemp oil for worldwide brands, with CBD as a value-added ingredient where legal. The company has a portfolio of products in the pain relief, skin health, sleep, anxiety and pet health categories. The company’s goal is to leverage its knowledge and experience with cannabis, and its licensed production facility for manufacturing and distribution, to deliver cannabis health care products for the everyday consumer. Geyser’s tinctures, creams, cosmetics, functional foods and beverages, and natural health products are made with all-natural, biocompatible, biodegradable, nontoxic and noninflammatory materials.

Geyser Brands subsidiary Apothecary Botanicals operates a Health Canada-approved licensed production facility based just outside of Vancouver, British Columbia. It received its cultivation license in 2018 and its processing license in June 2019. It is currently completing laboratory modifications in anticipation of receiving an R&D license in the short term.

Through Solace Management Group, Geyser Brands recently announced the world’s first hemp-infused, freeze-dried pet food (http://ibn.fm/Sb0bl). Upon completion of the Solace acquisition, Geyser anticipates that WildTails’ products will use its proprietary NanoFusion technology to infuse hemp into proteins such as beef, chicken and fish. Negotiations for order-and-distribution contracts are expected to be announced in Q3 2019.

Geyser Brands presents an intriguing investment opportunity as it establishes new brands with hemp ingredients in a variety of markets. One of 150 Health Canada-approved cannabis LPs, the company has a strong footprint in Canada as it expands its existing markets. Geyser continues to focus on building an integrated production chain and formulation lab that will develop innovative products for its customers.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• MustGrow’s patented technology derived from mustard seed utilizes the plant’s natural defense mechanisms
• The company’s first-generation granular technology may be fast-tracked for use in cannabis cultivation
• Its second-generation liquid formulation may be fast-tracked for use in cannabis and fruit & vegetable cultivation
• The economic impact of global crop losses due to parasitic nematodes is estimated at $100 billion per year

MustGrow Biologics Corp. is a private agricultural biotech company developing and commercializing specialized technology in the form of a natural biopesticide and bio-fertilizer that offers a much more palatable option for cannabis and fruit and vegetable growers that are unable to use synthetic pesticides and fertilizers. MustGrow’s novel, proprietary technology utilizes organic components refined from the mustard seed, leveraging the plant’s natural defense mechanism as a pre-plant/pot soil bio-fumigant/treatment to control soil-borne pests and diseases (http://ibn.fm/g9GQS).

The global fruit and vegetable market, along with the legal cannabis sector, is clearly ready for a proven product that certifies as an organic solution to an age-old problem for growers. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients. Damage from soil-borne parasitic nematodes causes about $100 billion in lost crops per year, with nematodes being responsible for up to 20 percent loss in certain fruit and vegetable crops (http://ibn.fm/pYufk).

MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. Continued use of modern synthetic crop protection products can create a resistance to these conventional products among pests. Advancements in integrated pest management solutions, along with an increase in organic farming, is expected to push the biopesticides market beyond $6 billion by 2023, ResearchandMarkets reports (http://ibn.fm/3v9FA).

MustGrow’s biopesticide has U.S. EPA (Environmental Protection Agency) and Canadian PMRA (Pest Management Regulatory Agency) labels as an approved organic solution. The company is also seeking approval to add cannabis as an accepted use, both in the U.S. and Canada. MustGrow’s research shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia and botrytis (gray mold) that affect the cannabis plant.

To date, the company has successfully completed more than 110 independent third-party field trials of its products. MustGrow is at the forefront of development of unique solutions to help fruit and vegetable growers and cannabis growers control pests and crop diseases.

For more information, visit the company’s website at www.MustGrow.ca

• Endonovo Therapeutics is developing bioelectronic devices that target patient pain, inflammation and wound recovery
• The company intends to get its flagship SofPulse device into 600 hospitals within the next 18 months as part of its bid to reduce post-operative drug dependence
• Drug dependence is regarded as a major contributor to a global opioid epidemic that has driven advocacy for less harmful pain drugs, increased governmental funding and new sentencing protocols for drug-related crimes
• The U.S. government has spent $2.4 billion during the past two years on addiction intervention amid statistics showing pain-killer death totals in the tens of thousands each year

Worldwide concerns about pain relief medication-induced addictions and deaths have led to a variety of societal changes during recent years, most notably driving the multinational advocacy for medical marijuana (cannabis) as a potential palliative without the degree of harmful effects from prescription and illegal narcotics, while also spawning increasing calls for governmental funding to fight addiction and change the judicial system’s approach to drug-related crimes. Amid some concerns about how private industry and governmental agencies are responding to the opioid epidemic/pandemic, Endonovo Therapeutics Inc. (OTCQB: ENDV) is advancing novel bioelectronic device solutions that are non-invasive and sidestep the drug issues entirely.

Endonovo Therapeutics is a commercial-stage developer of medical implements designed to provide proprietary, patent-protected electroceutical therapy for treating patient pain, inflammatory conditions, cardiovascular diseases and central nervous system disorders. The company’s flagship product, SofPulse, uses targeted electrical microcurrents to gently help reduce tissue swelling and speed up the natural recovery process.

Endonovo’s electroceutical therapy has received clearance for the palliative treatment of post-surgical pain and edema (swelling) from the U.S. Federal Drug Administration, has national coverage from the Centers for Medicare and Medicaid Services in chronic wound treatment and maintains a CE-mark certification that indicates conformity with European Economic Area health and environmental protection standards related to wound, pain and edema treatment.

On June 13, the company detailed its initial strategy for a national rollout of its SofPulse targeted pulsed electromagnetic field (tPEMF) therapy device to hospitals throughout the United States. According to the company’s news release, Endonovo plans to be in the evaluation stage with 600 hospitals within the next 18 months, employing 300 sales representatives (http://ibn.fm/gAHv2).

“After careful consideration and discussions, and in accordance with our internal budgets, we have reached the point at which we can confidently announce our national rollout plan and strategy,” CEO Alan Collier stated in a new release. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020. With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”

The federal government has provided at least $2.4 billion in grant money since 2017 to reduce opioid addiction, citing statistics reporting tens of thousands of drug addiction-related deaths each year, although reform advocates complain that the medical marijuana-fueled policy changes are too narrow in scope (http://ibn.fm/E67V1). Additional proposed legislation would provide a more widespread continuum of care for drug recovery, but at a cost of billions of dollars in taxpayer payouts (http://ibn.fm/5QOPp).

At the same time, media reports on new research are countering prior claims that states with legal medicinal marijuana had seen fewer opioid overdose deaths than states without legal medical cannabis, showing that addiction-related deaths in medical cannabis-legal states have actually been increasing (http://ibn.fm/X8gzJ) and indicating that “cannabinoids have demonstrated therapeutic benefits, but reducing population-level opioid overdose mortality does not appear to be among them,” according to a piece published by The Philadelphia Inquirer (http://ibn.fm/MPi3t).

Endonovo’s SofPulse device aims to elevate discussion of non-drug solutions to the addiction crisis (http://ibn.fm/tXlin), noting that, as the device reduces edema and pain levels, thereby decreasing the requirement for medication, “patients can move around sooner, which stimulates the body’s natural response to healing… (And) unlike prescription medications, SofPulse has no known side effects.” The company has filed an 8-K with the Securities and Exchange Commission, providing its new nationwide marketing plan with sales projections.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• The rising global popularity of cannabidiol as a wellness product is leading market forecasts of revenues up to $22 billion by 2022 and $50 billion or more by the end of the next decade
• The market optimism is fueling hopes for ancillary market players as well, such as hydroponics equipment supplier Sugarmade Inc.
• Sugarmade announced this month that it will enter the hemp CBD extraction equipment market, drawing on access to advanced Chinese extraction technologies

The health and wellness market sector for cannabidiol (CBD) products continues to grow at such a pace that analysts at the Brightfield Group predict that revenues could reach $22 billion per year by 2022 and, per various Wall Street estimates, approach $50 billion or even $75 billion by 2029-30, as noted in a media report carried by Nasdaq (http://ibn.fm/5Wlme).

The potency of CBD’s sales estimates are encouraging to Sugarmade Inc. (OTCQB: SGMD), which announced this month that it is expanding on its hydroponics supply model for the agriculture industry to enter the hemp extraction equipment and technologies market (http://ibn.fm/RIIAy). In addition to supplying “legacy extraction equipment to extraction companies,” Sugarmade plans to begin distribution of “next generation extraction technologies developed in the Chinese province of Yunnan where the hemp industry has existed for more than a thousand years,” CEO Jimmy Chan stated in a news release.

The proprietary Chinese technologies hold the promise of increasing the efficiency of production processes used in hemp cultivation and extraction – the primary source of CBD – at a time when hemp cultivation is enjoying a resurgent popularity in the United States in tandem with federal legalization under last year’s Farm Bill (http://ibn.fm/W0vuh).

“It is clear the 2019 and 2020 hemp cultivation seasons will be massive,” Chan added. “Our staff has done extensive research into the fast-growing hemp industry. We continue to see an imbalance between cultivation outputs and extraction capacities within the industry. This leads us to believe the market for extraction services and the equipment required by these extraction companies will continue to accelerate.”

The company cites U.S. Department of Agriculture forecasts anticipating that farm production will generally decrease nationwide, while hemp production is expected to defy the trend as states such as Kentucky, Colorado, Oregon and North Dakota report sizable increases in hemp acreage and applications to begin cultivating hemp. In April, Kentucky’s state agriculture commissioner told a CNBC news reporter that he expects the number of hemp acres in Kentucky to increase from 16,000 to 50,000 this year, with a corresponding increase in applications for hemp cultivation (http://ibn.fm/e0Qsq).

Sugarmade has been building on an agreement with Kentucky-based hemp cultivator Hempistry Inc. to deliver resources for plant micropropagation work. Micropropagation involves cloning or “propagating” new hemp plants from existing “mother” plants that demonstrate superior qualities. A lot of North America’s hemp is grown using propagation techniques instead of by planting new seeds, which may carry greater risks of poor productivity. The propagation technique also allows the company to harvest a large number of plants simultaneously.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• The Green Organic Dutchman is a premium, international organic cannabis company
• TGOD recently secured a cannabis supply agreement with Alberta Gaming, Liquor and Cannabis
• The company has a partnership with the world’s second-largest power-management company

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) grows high-quality, organic cannabis with sustainable, all-natural principles. A premium global organic cannabis company headquartered in Mississauga, Ontario, TGOD focuses on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD’s products are laboratory tested to ensure that patients have access to a standardized, safe, consistent product. The company’s organic process involves transparent, sustainable steps and principles to produce certifiable quality.

TGOD has a planned capacity of 219,000 kg and is constructing 1.64 million square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. Additionally, TGOD has organic hemp, CBD oil operations in Canada. Furthermore, through wholly owned subsidiary HemPoland, the company distributes premium hemp CBD oil in the European Union. TGOD’s Ancaster, Ontario, operations span 166,000 square feet of high-tech facilities capable of producing 17,500 kg of high-quality organic cannabis annually (http://ibn.fm/qATad).

Recently, TGOD announced its entry into a cannabis supply agreement with Alberta Gaming, Liquor and Cannabis (AGLC). This further expands TGOD’s presence in Western Canada. AGLC, under the brand Alberta Cannabis, is Alberta’s legal, nonmedical, online cannabis store (http://ibn.fm/LJyIf).

The agreement with AGLC was negotiated in association with Velvet Management Inc. Velvet Management provides a fully integrated, national sales and distribution platform for TGOD’s premium organic cannabis to provincial liquor and cannabis boards.

“Alberta is an important market for us as we continue to expand our distribution channels across Canada,” TGOD CEO Brian Athaide said in a news release. “With our production facilities in Hamilton, Ontario, and Valleyfield, Quebec, coming online in phases, we are thrilled to start distributing TGOD’s premium certified-organic cannabis to AGLC.”

TGOD also recently reported the distribution of unit purchase warrants (“SpinCo Unit Warrants”) of TGOD Acquisition Corp. (“SpinCo”) to all registered TGOD shareholders of record as of January 31, 2019, who elected to receive the SpinCo Unit Warrants under the company’s earlier announced plan of arrangement with SpinCo (http://ibn.fm/EUgib). SpinCo is an investment company guided by an investment policy that’s mainly focused on investments in the cannabis industry in Canada and worldwide.

TGOD has a partnership with Eaton, the world’s second-largest power-management company. Eaton promises to supply innovative and cost-effective power solutions to meet TGOD’s increasing demands. In addition, construction management is supplied by Ledcor, Canada’s second-largest multidisciplinary construction company. Ledcor is a pioneer in the green building industry.

The future for TGOD includes its strategic beverage division. The expectation is that this will be an organic research and development (R&D) center, which will focus on novel and proprietary cannabinoid-infused beverages, advanced product development and pilot manufacturing for novel and proprietary cannabinoid-infused beverages, advanced product development and pilot manufacturing (http://ibn.fm/1XOwi).

TGOD continues to focus on first-class products that demand a premium in the market. With its strategic partnerships, global growth and world-class executive team, the company offers investors the potential for healthy ROI. By growing organically and operating at low costs, TGOD is well positioned to become the worldwide leader in delivering premium organic-cannabis solutions designed to enhance lives.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Willow has entered a joint development agreement with Noramco Inc. that includes a plan to develop a yeast-based biosynthesis platform to produce low-cost CBD for the pharmaceutical, food, beverage and personal care markets
• The agreement has the potential to open the door to new and larger markets for CBD and related compounds
• Terms of the agreement call for the parties to cover their own costs, retain their own intellectual property (IP) and share equally in gross profits

Willow Biosciences Inc. (CSE: WLLW) has entered a joint development agreement (“JDA”) with Noramco Inc. to develop a biosynthesis platform for the production of CBD (http://ibn.fm/2ig1X). The result could be far-reaching, developing low-cost, ultra-pure CBD products for pharmaceutical, food, beverage and personal care consumers. The work has the potential to provide access to new and larger markets for CBD and related compounds.

The JDA requires each company to cover its own costs, retain its own intellectual property associated with its own scopes of work and share equally in the gross profits from sales of CBD produced under the agreement.

Based in Calgary, Canada, Willow Biosciences produces high-value, plant-derived biosynthetic compounds. In the cannabinoid field, the company owns proprietary, yeast-based lab strains that produce CBD, THC and cannabigerol (CBG), as well as other minor and novel cannabinoids. Noramco, based in Wilmington, Delaware, is the world’s largest producer of high-quality synthetic cannabinoid active pharmaceutical ingredients (API) for the pharmaceutical and health care industry.

The JDA calls for WLLW to be responsible for optimizing yeast strains in a biosynthetic process that is expected to generate ultra-pure CBD at a lower cost and higher yield than current methods. Noramco will be responsible for scale up, regulatory submission, marketing and distribution.

“They are the obvious first choice as a partner to scale the development of our CBD biosynthesis program,” WLLW Executive Chair Dr. Joseph Tucker stated in a news release (http://ibn.fm/LjPRC). “Noramco’s global leadership program in the production and sales of cannabinoids to pharmaceutical companies will naturally lead into manufacturing and sales into additional nonpharmaceutical markets.”

Bill Grubb, Noramco’s chief innovation officer and VP of global business development, said in a news release (http://ibn.fm/Eh68Y) that the agreement would give Noramco “the capacity to address rapidly increasing market demand for CBD-based APIs and ingredients from pharmaceutical, nutraceutical, consumer packaged goods, beverage and other industry sectors.”

For more information, visit the company’s website at www.WillowBio.com

• Plus Products has the right – but no obligation – to buy Emerald Bay Wellness and the business assets of Emerald Bay Extracts
• Emerald Bay Extracts has been one of Plus Products’ largest suppliers for the past year
• If the option is exercised, PLUS will reap the benefits of vertical integration and directly interact with the cannabis plant

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), manufacturer and marketer of cannabis food products, has purchased an option to buy California-based cannabis oil manufacturer Emerald Bay Wellness LLC and the business assets of Emerald Bay Extracts. The option specifies cash and stock consideration for PLUS to acquire one of its largest cannabis oil suppliers and a supply partner for more than a year (http://ibn.fm/8rbu3).

In consideration for the option, PLUS intends to deliver a $400,000 secured loan to Emerald Bay Extracts. If the acquisition option is exercised, terms call for the issuance of approximately 1.2 million subordinate voting shares of PLUS and $250,000 in cash; in addition, Emerald Bay would not be required to repay the original loan. Some 70 percent of the deal’s consideration would be subject to performance revenue, which totals almost $28 million over a two-year, earn-out period (http://ibn.fm/H4B7a).

“We targeted this acquisition because it allows us to reap the benefits of vertical integration while maintaining a focus on product manufacturing,” PLUS CEO Jake Heimark stated in a news release (http://ibn.fm/ETibU). “Ultimately, this is a rare opportunity to improve quality control, cut costs and grow revenues all at the same time.” Heimark added that acquiring Emerald Bay would give PLUS the opportunity to “directly interact with the cannabis plant.”

If exercised, the option would give Plus Products in-house cannabis extraction capabilities that could improve quality control and raise gross margins on its core edibles business. Exercising the option could also create a new revenue stream and product development capabilities.

San Mateo, California-based PLUS is a cannabis-infused branded products manufacturer selling to regulated medicinal and adult-use recreational markets in California and Nevada. PLUS is focused on building the largest cannabis brand by growing organically and through acquisitions.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF